succinate and hydrocortisone are chromatographed with a mobile phase consisting of sodium acetate! acetonitnle (77/23, by vol), the effluent being monitored at 254 nm. p-Hydroxybenzoate-N-propyl is used as the internal standard. Detection limits are 0.5 mg/L for hydrocortisone succinate, 0.2 mg/L for hydrocortisone. For five different concentrations the respective mean analytical recoveries were 88.2% and 100.5%, the mean intra-assay CVs for slope 3.9% and 2.1%, and the inter-assay CV5 3.3% and 1.6%.
and hydrocortisone sodium succinate were from Nikken Chemicals Co., Ltd., Tokyo, Japan. Hydrocortisone succinate was from Hoechst Japan Ltd., Tokyo, Japan. Methanol, p-hydroxybenzoate-N-propyl, acetonitrile, sodium acetate, sodium chloride, and glacial acetic acid were from Wako Pure Chemical Industries Ltd., Osaka, Japan. Solvents and all other chemicals were analytical Chromatographic conditions. For reversed-phase chromatography, prepare a mobile phase by mixing 0.05 molJL sodium acetate buffer (adjusted to pH 2.8 with acetic acid, and containing 0.1 mol sodium chloride per liter) with acetonitrile (77/23, by vol). This mixture is delivered at a flowrateof2.5 mLfmin at room temperature.Monitor the column effluent at 254 nm, a wavelength thatis common to essentially all HPLC instruments containinga mercury lamp and that yields nearly optimum absorbance of several corticosteroids (1). Set the sensitivity of the detector to 0.01 A full scale, and the recorder chart speed to 5 mmlmin.
Calibration and reproducibility.
As a reagent for the calibration curve and analytical recovery, we used hydrocortisone succinate; hydrocortisone sodium succinate is hygroscopic and the pure material can be recrystallized only with difficulty. Methanolic solutions of hydrocortisone succinate and hydrocortisone were each diluted with distilled water to give concentrations from 0.5 to 10 mgIL. To 1 mL of the solution we added 2 mL of methanolic solution containing the internal standard (2 mgfL) and injected 50 zL onto the column. Calibration curves were plots of peak-height ratios of individual hydrocortisone succinate and hydrocortisone peaks vs the amount injected.
We evaluated analytical recovery and reproducibility by adding 100 .L of a solution containing 0.51 to 10.20 mg!L (for hydrocortisone succinate) or 0.53 to 10.68 mgfL (for hydrocortisone) to lyophilized pooled serum and assaying. Samples were taken through the whole procedure and results calculated by use of calibration curves.
Subjects and plasma sample collections. We studied three asthmatic children (13 to 14 years) admitted with asthmatic attack. sone (as hydrocortisone sodium succinate) per kilogram of body weight without any other bronchodilators over 12 h, and corticosteroids three days beforethe study.No adverse effects were observedduringorafter theinjection. Bloodwas sampled from an indwellingneedlein the opposite antecubitalveinbefore and 5, 10,15,30,60,120,and 240 mm after the drug injection. The blood samples were dispensed into tubes containing tetrasodiwnEDTA as anticoagulant. The tubes were centrifuged at 1500 x g for 10 mm, and the separated plasmas were storedat -20 #{176}C untilanalysis.
Other procedures. To compare the performance of the HPLC method with that of radioimmunoassay (RIA) , we measured the concentrations of hydrocortisone in plasma samples from asthmatic children treated with intravenous hydrocortisone by a specific radioimmunoassay with a SPAC Cortisol kit (Daiichi Radioisotope Labs, Ltd., Tokyo, Japan). Antiserum to 6a-hydroxycortisol 6-hemisuccinatebovine serum albumin conjugate was raised in rabbits (9); its cross reactivity with hydrocortisone succinate was <2% (10).
Results

Figure 1 shows representative chromatogranis
for a reconstituted extract of a plasma sample to which a standard solution of anti-asthmatic drugs-theophylline, salbutamol, orciprenaline, terbutaline, noscapine, tipepidine hibenzate, p-hydroxybenzoate-N-propyl, hydrocortisone succinate, and bromhexine-had been added; for an extract of a blank plasma sample; and for an extract of a plasma sample from one of the asthmatic children treated with the single intravenous injection described. Blank plasma assayed by this procedure showed no peaks that might noticeably interfere with the analysis. Under the conditions specified, the respective retention times for hydrocortisone, We measured hydrocortisone in 13 plasma samples by Table 1 . Pharmacokinetlc Parameters of both RIA (y) and HPLC (x) . The regression equation for the results was: y = 0.913x + 0.300; r = 0.929 (P <0.001) Hydrocortisone Succinate and Hydrocortisone In Plasma after Administration of Hydrocortlsone Sodium (Figure 4) . Figure 5 shows data for a typical concentration-time
Succinate (Hydrocortisone at 5 mg/kg Body Weight)
curve after intravenous administration of hydrocortisone P0's Hydrocortlsone succinate sodium succinate to the three asthmatic children. 
Discussion
Our procedure is rapid, specific, and reproducible.Of the In the present method, plasma samples were simply extracted once with methanol.
The choice of p-hydroxybenzoate-N-propyl as internal standard, which has a retention time between those of the two compounds being measured, also contributes to the rapid analysis time. The detection limits were not adequately 2.0 2.5 3.0 sensitive to monitor hydrocortisone at the low concentrations normally found in plasma. However, our method in allows simultaneous assay of the drug and its metabolite in plasma after injection. It is sensitive enough for routine application in pharmacokinetic studies and drug monitoring. Indeed, a hydrocortisone peak appears in chromatograms of plasma samples as the hydrocortisone succinate concentration approaches its maximum and then decreases rapidly. This confirms the observation of Smith (6), and provides further evidence of the metabolism of hydrocortisone succinate to hydrocortisone.
Although relatively large doses of corticosteroids are usually recommended for the treatment of acute severe asthma, the precise optimal amount required has not been clearly delineated (8) . Early studies recommended the hydrocortisone concentration of 1 mg/L in plasma as the minimum necessary to achieve a therapeutic response. The Section on Allergy and Immunology of the American Academy of Pediatrics recommended (11) that an initial loading doseof corticosteroid equivalent to 1-2 mg of prednisone per kilogram of body weight be administered intravenously, followed by an equivalent dosage over the next 24 h. Elimination half-lives of hydrocortisone in plasma in the present study were in agreement with values found by other investigators (12 13). The hydrocortisone concentrations in plasma could be kept above 1 mgfL for >2 h after the administration. These findings indicate that adequate concentrations of the drug in plasma can be achieved by an intravenous injection of hydrocortisone at 5 mg/kg body _____ weight. Further study is needed to elucidate pharmacodynamics (the relationship between hydrocortisone concentration in plasma and anti-asthmatic effects) in the treatment of acute severe asthma.
